Daewoong Pharmaceutical Presents Baseline Characteristics of 104 Patients in Global Phase 2 Trial for IPF Drug Candidate 'Bersiporocin' at ERS 2026
BARCELONA, Spain and SEOUL, South Korea, Sept. 24, 2026 // -- Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Changjae Lee) announced that it presented a poster on the baseline characteristics of all 104 patients enrolled in the global Phase 2 clinical trial of its idiopathic pulmonary…